Xbrane Surges 50% as FDA Approves Lucamzi

The FDA approved Xbrane's drug Lucamzi, causing shares to surge over 50%. This approval is a significant milestone for the biotech firm, expanding patient access. The market reaction reflects high expectations for commercial success, but actual sales performance remains uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works